Inorganic Nitrate Treatment Cuts Rate of Contrast-Induced Nephropathy
By Elana Gotkine HealthDay Reporter
THURSDAY, March 28, 2024 -- For patients presenting with acute coronary syndromes (ACS) undergoing coronary angiography, inorganic nitrate treatment reduces the rate of contrast-induced nephropathy (CIN), according to a study published online March 21 in the European Heart Journal.
Daniel A. Jones, M.D., Ph.D., from the Queen Mary University of London, and colleagues conducted a double-blind, randomized trial to assess the efficacy of inorganic nitrate in CIN prevention in at-risk patients presenting with ACS. Patients were randomly assigned to receive once-daily potassium nitrate (12 mmol) or placebo (319 and 321, respectively) for five days.
The researchers found that the rates of CIN were significantly reduced with inorganic nitrate treatment versus placebo (9.1 versus 30.5 percent, respectively). After adjustment for baseline creatinine and diabetes status, the difference persisted (odds ratio, 0.21). Improvements were seen in secondary outcomes with inorganic nitrate versus placebo, with significantly lower rates of procedural myocardial infarction (2.7 versus 12.5 percent), improved three-month renal function (between-group change in estimated glomerular filtration rate, 5.17), and significantly reduced one-year major adverse cardiac events (MACE; 9.1 versus 18.1 percent).
"In patients at risk of kidney injury undergoing coronary angiography for ACS, dietary inorganic nitrate reduces CIN compared to placebo," the authors write. "This corresponded to improved kidney outcomes at three months and MACE events at 12 months, findings which could have important implications for reducing the burden on the National Health Service."
One author disclosed being a director of HeartBeet Ltd.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.